Recent share performance context

HCA Healthcare (HCA) has drawn attention after a recent pullback, with the stock down about 14% over the past month and 30% over the past 3 months, despite a modest 1-year total return of 3%.

Short term, the stock has been under pressure, with the 30 day share price return down 13.85% and the 90 day share price return down 30.22%. At the same time, the 5 year total shareholder return of 86.19% reflects a much stronger longer term picture.

If you are reassessing your healthcare exposure after HCA Healthcare's recent swings, it can be useful to see what else is moving in the sector using the 39 healthcare AI stocks

With HCA Healthcare trading at $374.90, along with ongoing revenue and net income growth and indications of a discount to some valuation estimates, you have to ask: is this a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 40.4% Undervalued

HCA Healthcare's most followed valuation narrative, according to yiannisz, places fair value at about $629.14 per share, well above the recent $374.90 close. That gap rests on a view that HCA's scale, cash generation and role in US healthcare can support a higher long term valuation than the market is currently implying.

In a market that often swings between hype and fear, HCA Healthcare (NYSE: HCA) stands out for a different reason: consistency. While much of the healthcare sector wrestles with reimbursement uncertainty, labor costs, and regulatory noise, HCA continues to operate from a position of scale and operational discipline. It’s not flashy, but it’s effective.

The fair value call leans heavily on HCA's size, its ability to keep facilities full and productive, and disciplined use of cash across buybacks and reinvestment. Want to see how those moving pieces, plus measured growth in revenue and margins, are combined into a single valuation story? The key levers are all laid out in that narrative, including how the required return of investors is handled and what kind of earnings profile this business might sustain over time.

Result: Fair Value of $629.14 (UNDERVALUED)

However, this hinges on reimbursement conditions and labor costs not tightening further, because either could pressure margins and weaken confidence in that undervaluation case.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If this mix of optimism and concern feels familiar, you are not alone. Take this opportunity to review both sides of the story with the 5 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that might fit your goals even better, so keep your idea pipeline open.

• Scan for quality at a discount by checking companies highlighted in the 46 high quality undervalued stocks.
• Strengthen your income focus by reviewing stocks in the 9 dividend fortresses.
• Prioritise resilience by looking at companies inside the 63 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.